Posted by Michael Wonder on 23 Nov 2016
TGA approves extended use of Harvoni
23 November 2016 - The TGÅ has approved the use of Harvoni in additional genotypes.
The TGA approved Harvoni (ledipasvir with sofosbuvir) for the treatment of adults patients with genotype 2, 3 ,4, 5 and 6 chronic hepatitis C infection.
